AI and the Future of Pharmacovigilance
Today’s data explosion is forcing pharmacovigilance professionals to use artificial intelligence technologies to get answers in a more proactive way. “Just putting 100 more people in a room and trying to look at documents and bounce ideas off of each other’s head isn’t going to work anymore,” says Bruce Donzanti, former Senior Group Director, Global Regulatory Pharmacovigilance Innovation Policy at Genentech.
Donzanti joins the podcast for a lively discussion about the evolution of pharmacovigilance and how pharma companies and health authorities are working together to advance the future of safety science.
In this episode of Safety Signals, we discuss:
– How AI has become a necessity, not just a nice-to-have
– How human biases have plagued the industry for decades
– The quest for rapid access to quality data
* The views of the hosts and guests featured on Safety Signals are their own and do not necessarily reflect the views of Saama or the individual companies for which the guests may work.
About Saama Safety Signals
Introducing Safety Signals, the show for pharmacovigilance professionals, benefit risk managers, epidemiologists, and other patient safety stakeholders. From pharma leaders to academics and scientists, we provide expert perspectives on the challenges, opportunities, and technologies that are shaping the future of the safety sciences. Get ready to be inspired and energized as you work to reduce the risk of life-changing–and life SAVING–medical treatments.
Meet Your Hosts & Guests
Vice President & Partner
Former Senior Group Director, Global Regulatory Pharmacovigilance Innovation Policy